Catalysts · MRK · CIK 310158 · page 3 of 4

MRK catalysts and FDA events, page 3.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on MRK PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
August 2029Month disclosed9vhpv vaccine (V503)MRKPrimary completionPapillomavirus InfectionsScheduledClinicalTrials.gov
August 2029Month disclosedVerquvo (vericiguat)MRKPrimary completionHeart Failure; Left Ventricular Systolic DysfunctionScheduledClinicalTrials.gov
Sep to Dec 2029Quarter discloseddor/isl (MK-8591A)MRKTopline readoutHIV-1; HIV InfectionScheduledClinicalTrials.gov
September 2029Month discloseddor/isl (MK-8591A)MRKPrimary completionHIV-1; HIV InfectionScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosed9vhpv vaccine (V503)MRKTopline readoutPapillomavirus InfectionsScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutMelanomaScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosedtulisokibart (PRA023)MRKTopline readoutPulmonary SarcoidosisScheduledClinicalTrials.gov
October 2029Month disclosedtulisokibart (PRA023)MRKPrimary completionPulmonary SarcoidosisScheduledClinicalTrials.gov
October 2029Month disclosed9vhpv vaccine (V503)MRKPrimary completionPapillomavirus InfectionsScheduledClinicalTrials.gov
October 2029Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionMelanomaScheduledClinicalTrials.gov
Nov 2029 to Feb 2030Quarter disclosedLipfendra (enlicitide decanoate)MRKTopline readoutArteriosclerosis; HypercholesterolaemiaScheduledClinicalTrials.gov
Nov 2029 to Feb 2030Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutMalignant NeoplasmScheduledClinicalTrials.gov
November 2029Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionMalignant NeoplasmScheduledClinicalTrials.gov
November 2029Month disclosedLipfendra (enlicitide decanoate)MRKPrimary completionArteriosclerosis; HypercholesterolaemiaScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutBreast Neoplasms; Breast CancerScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedcalderasib (MK-1084)MRKTopline readoutNon-small Cell Lung CancerScheduledClinicalTrials.gov
December 2029Month disclosedcalderasib (MK-1084)MRKPrimary completionNon-small Cell Lung CancerScheduledClinicalTrials.gov
December 2029Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionBreast Neoplasms; Breast CancerScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedWINREVAIR (sotatercept)MRKTopline readoutPulmonary HypertensionScheduledClinicalTrials.gov
January 2030Month disclosedWINREVAIR (sotatercept)MRKPrimary completionPulmonary HypertensionScheduledClinicalTrials.gov
Feb to May 2030Quarter disclosedmiransertib (MK-7075)MRKTopline readoutPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)ScheduledClinicalTrials.gov
February 2030Month disclosedmiransertib (MK-7075)MRKPrimary completionPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)ScheduledClinicalTrials.gov
May to Aug 2030Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutTriple Negative Breast NeoplasmsScheduledClinicalTrials.gov
May 2030Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionTriple Negative Breast NeoplasmsScheduledClinicalTrials.gov
Jun to Sep 2030Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutNon-small Cell Lung CancerScheduledClinicalTrials.gov
June 2030Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionNon-small Cell Lung CancerScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
June 24, 2026Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 23, 2026KEYTRUDA® (pembrolizumab)MRKTopline readoutAdvanced Hepatocellular CarcinomaCompletedClinicalTrials.gov
June 19, 2026WELIREG® (belzutifan)MRKPDUFA date—ApprovedSEC 8-K Exhibit 99.1
June 15, 2026pembrolizumab/vibostolimab (MK-7684A)MRKPrimary completionCarcinoma, Non-Small-Cell LungCompletedClinicalTrials.gov
June 12, 2026KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2026Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2026WELIREG® (belzutifan)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 8, 2026KEYTRUDA® (pembrolizumab)MRKTopline readoutColorectal CancerCompletedClinicalTrials.gov
June 8, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionSolid TumorsCompletedClinicalTrials.gov
June 8, 2026KEYTRUDA® (pembrolizumab)MRKTopline readoutAdvanced Non-Small Cell Lung CancerCompletedClinicalTrials.gov
June 5, 2026MK-1167MRKPrimary completionAlzheimer Disease; DementiaWithdrawnClinicalTrials.gov
June 1, 2026efinopegdutide (MK-6024)MRKTopline readout—CompletedClinicalTrials.gov
April 30, 2026—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
April 28, 2026IDVYNSO (doravirine-islatravir)MRKPDUFA date—ApprovedSEC 8-K Exhibit 99.1
April 24, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionBreast NeoplasmsCompletedClinicalTrials.gov
April 24, 2026Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
April 21, 2026zilovertamab vedotin (MK-2140)MRKPrimary completionRelapsed or Refractory Diffuse Large B-Cell LymphomaCompletedClinicalTrials.gov
April 20, 2026IDVYNSO (doravirine-islatravir)MRKFDA approval—ApprovedFDA Novel Drug Approvals
April 9, 2026frespaciguat (MK-5475)MRKPrimary completionPulmonary Hypertension; Chronic Obstructive Pulmonary DiseaseCompletedClinicalTrials.gov
April 7, 2026KEYTRUDA® (pembrolizumab)MRKPDUFA date—ScheduledSEC 8-K Exhibit 99.1
April 2, 2026tulisokibart (PRA023)MRKPrimary completionHidradenitis SuppurativaCompletedClinicalTrials.gov
March 12, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionLung Cancer; Non-Small Cell Lung CancerCompletedClinicalTrials.gov
March 12, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionSolid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial CancerCompletedClinicalTrials.gov
March 5, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionCarcinoma, Squamous Cell; Skin NeoplasmsWithdrawnClinicalTrials.gov
February 20, 2026MVASI® (bevacizumab)MRKPDUFA date—ScheduledSEC 8-K Exhibit 99.1
February 10, 2026KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
February 10, 2026Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
February 4, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionCarcinoma, Renal CellCompletedClinicalTrials.gov
February 4, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionCarcinoma, Renal CellCompletedClinicalTrials.gov
February 3, 2026—MRKTrial start—CompletedSEC 8-K Exhibit 99.1
February 3, 2026—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
February 2, 2026WELIREG® (belzutifan)MRKPrimary completionCarcinoma, Renal CellCompletedClinicalTrials.gov
January 27, 2026Noxafil (posaconazole)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionBladder CancerCompletedClinicalTrials.gov
January 21, 2026Verquvo (vericiguat)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 21, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completion—CompletedClinicalTrials.gov
January 14, 2026KEYTRUDA® (pembrolizumab)MRKPrimary completionHodgkin LymphomaCompletedClinicalTrials.gov
December 29, 2025efinopegdutide (MK-6024)MRKPrimary completionNon-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLDCompletedClinicalTrials.gov
December 22, 2025V114MRKPrimary completionAcute Otitis Media (AOM)CompletedClinicalTrials.gov
December 9, 2025Recarbrio (cilastatin sodium; imipenem; relebactam)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 21, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 21, 2025Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 20, 2025WINREVAIR (sotatercept)MRKPrimary completionPulmonary Arterial HypertensionCompletedClinicalTrials.gov
November 5, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionBladder CancerWithdrawnClinicalTrials.gov
Nov 2025Month disclosedIDVYNSO (doravirine-islatravir)MRKTopline readoutHIV-1 infection in previously untreated adults, and in November 2025, the CompanyPositiveSEC Form 10-K
October 31, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionCarcinoma, Non-Small-Cell LungCompletedClinicalTrials.gov
October 30, 2025—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
October 27, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionBladder CancerCompletedClinicalTrials.gov
October 25, 2025WINREVAIR (sotatercept)MRKPDUFA date—ScheduledSEC 8-K Exhibit 99.1
October 24, 2025Winrevair (sotatercept-csrk)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 16, 2025dor/isl (MK-8591A)MRKPrimary completionHIV InfectionCompletedClinicalTrials.gov
October 15, 2025bla761495MRKFDA approval—ApprovedopenFDA Drugs@FDA
October 14, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionTriple Negative Breast NeoplasmsCompletedClinicalTrials.gov
October 13, 2025dor/isl (MK-8591A)MRKPrimary completionHIV-1 InfectionCompletedClinicalTrials.gov
September 23, 2025KEYTRUDA® (pembrolizumab)MRKPDUFA date—ScheduledSEC 8-K Exhibit 99.1
September 19, 2025Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)MRKFDA approval—ApprovedFDA Novel Drug Approvals
September 3, 2025favezelimab/pembrolizumab (MK-4820A)MRKPrimary completionHodgkin LymphomaCompletedClinicalTrials.gov
Sep 2025Month disclosedLIPFENDRA (enlicitide)MRKTopline readoutwith hypercholesterolemiaPositiveSEC Form 10-Q
Sep 2025Month disclosedMK-3475AMRKFDA approval—ApprovedSEC 8-K Exhibit 99.1
August 19, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionCarcinoma, HepatocellularWithdrawnClinicalTrials.gov
August 12, 2025LYNPARZA® (olaparib)MRKPrimary completionAdvanced Solid NeoplasmsCompletedClinicalTrials.gov
August 5, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completion—CompletedClinicalTrials.gov
July 30, 2025MK-6194MRKPrimary completionSystemic Lupus ErythematosusWithdrawnClinicalTrials.gov
July 29, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionAdvanced Hepatocellular CarcinomaCompletedClinicalTrials.gov
July 28, 2025Lipfendra (enlicitide decanoate)MRKPrimary completionHypercholesterolemia; Familial HypercholesterolemiaCompletedClinicalTrials.gov
July 25, 2025—MRKEarnings—CompletedSEC 8-K Exhibit 99.1
July 24, 2025KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 27, 2025efinopegdutide (MK-6024)MRKPrimary completion—CompletedClinicalTrials.gov
June 23, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionSmall Cell Lung CancerCompletedClinicalTrials.gov
June 23, 2025cisplatin (DMS32212R)MRKPDUFA date—ScheduledSEC 8-K Exhibit 99.1
June 13, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionAdvanced Non-Small Cell Lung CancerCompletedClinicalTrials.gov
June 10, 2025ENFLONSIA (clesrovimab)MRKPDUFA date—ScheduledSEC Form 10-Q
June 9, 2025Enflonsia (clesrovimab-cfor)MRKFDA approval—ApprovedFDA Novel Drug Approvals
June 6, 2025KEYTRUDA® (pembrolizumab)MRKPrimary completionUrinary Bladder Cancer, Muscle-invasiveCompletedClinicalTrials.gov
Every catalyst is quoted from MRK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.